Indian generic drug maker Natco gains 11% after FDA approval for diabetes drug, amid regulatory updates and profit rise.

Cellectis, a Paris-based biotech developing gene-edited cancer therapies, received a "Moderate Buy" rating with a $6.33 average 12-month target.

A new minimally invasive heart procedure is now available in Palm Beach County, offering faster recovery and lower risks for patients with severe blockages.

IGC Pharma gained U.S. and Canadian patent protection for its experimental Alzheimer’s drug IGC-AD1, a major step toward development and potential market launch.

Zentek updated on Feb. 17, 2026, about progress in its drug development pipeline and regulatory engagement with the FDA, without new approvals.

A 2026 study found AMD3100, an approved drug, helps immune cells attack rare liver cancer by reversing their exclusion from tumors.

CritiCare Asia Hospitals in Mumbai launched the Smith+Nephew CORI robotic system for precise, minimally invasive joint replacements, enhancing recovery and care access.

A 5-year-old in India recovered from a rare rectal condition after a successful complex procedure at Medicover.

Neflamapimod, targeting neuroinflammation, is being tested in up to 80 ALS patients in a UK trial.

Regentis Biomaterials expanded its European clinical sites to boost patient recruitment and trial efficiency.